153 related articles for article (PubMed ID: 15467035)
1. Predicting resistance or response to chemotherapy by proton magnetic resonance spectroscopy in neuroblastoma.
Lindskog M; Spenger C; Jarvet J; Gräslund A; Kogner P
J Natl Cancer Inst; 2004 Oct; 96(19):1457-66. PubMed ID: 15467035
[TBL] [Abstract][Full Text] [Related]
2. Low dose of arsenic trioxide inhibits multidrug resistant-related P-glycoprotein expression in human neuroblastoma cell line.
Liu L; Li Y; Xiong X; Qi K; Zhang C; Fang J; Guo H
Int J Oncol; 2016 Dec; 49(6):2319-2330. PubMed ID: 27840903
[TBL] [Abstract][Full Text] [Related]
3. Proton magnetic resonance spectroscopy in neuroblastoma: current status, prospects and limitations.
Lindskog M; Spenger C; Klason T; Jarvet J; Gräslund A; Johnsen JI; Ponthan F; Douglas L; Nordell B; Kogner P
Cancer Lett; 2005 Oct; 228(1-2):247-55. PubMed ID: 15946794
[TBL] [Abstract][Full Text] [Related]
4. The development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitro.
Piskareva O; Harvey H; Nolan J; Conlon R; Alcock L; Buckley P; Dowling P; Henry M; O'Sullivan F; Bray I; Stallings RL
Cancer Lett; 2015 Aug; 364(2):142-55. PubMed ID: 25960282
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive estimation of tumour viability in a xenograft model of human neuroblastoma with proton magnetic resonance spectroscopy (1H MRS).
Lindskog M; Kogner P; Ponthan F; Schweinhardt P; Sandstedt B; Heiden T; Helms G; Spenger C
Br J Cancer; 2003 Feb; 88(3):478-85. PubMed ID: 12569394
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide.
Keshelava N; Davicioni E; Wan Z; Ji L; Sposto R; Triche TJ; Reynolds CP
J Natl Cancer Inst; 2007 Jul; 99(14):1107-19. PubMed ID: 17623797
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Vassal G; Terrier-Lacombe MJ; Bissery MC; Vénuat AM; Gyergyay F; Bénard J; Morizet J; Boland I; Ardouin P; Bressac-de-Paillerets B; Gouyette A
Br J Cancer; 1996 Aug; 74(4):537-45. PubMed ID: 8761367
[TBL] [Abstract][Full Text] [Related]
8. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of galectin-1 facilitated cisplatin sensitivity by inhibiting autophagy in neuroblastoma cells.
Gao J; Wang W
Chem Biol Interact; 2019 Jan; 297():50-56. PubMed ID: 30365942
[TBL] [Abstract][Full Text] [Related]
10. Differential drug sensitivity of human neuroblastoma cells.
Spengler BA; Ross RA; Biedler JL
Cancer Treat Rep; 1986 Aug; 70(8):959-65. PubMed ID: 3731152
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
Keshelava N; Groshen S; Reynolds CP
Cancer Chemother Pharmacol; 2000; 45(1):1-8. PubMed ID: 10647494
[TBL] [Abstract][Full Text] [Related]
12. NSAIDs in neuroblastoma therapy.
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Cancer Lett; 2005 Oct; 228(1-2):195-201. PubMed ID: 15975708
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy.
Keshelava N; Seeger RC; Groshen S; Reynolds CP
Cancer Res; 1998 Dec; 58(23):5396-405. PubMed ID: 9850071
[TBL] [Abstract][Full Text] [Related]
14. Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Darpolor MM; Kennealey PT; Le HC; Zakian KL; Ackerstaff E; Rizwan A; Chen JH; Sambol EB; Schwartz GK; Singer S; Koutcher JA
NMR Biomed; 2011 Nov; 24(9):1159-68. PubMed ID: 21994185
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia.
Karlsson J; Edsjö A; Påhlman S; Pettersson HM
Mol Cancer Ther; 2005 Jul; 4(7):1128-35. PubMed ID: 16020671
[TBL] [Abstract][Full Text] [Related]
16. Combination of gamma-interferon with TRAIL and cisplatin or etoposide induces apoptosis in human neuroblastoma cell line SH-SY5Y.
Tong HX; Lu CW; Zhang JH; Ma L; Zhang JH
Chin Med Sci J; 2007 Mar; 22(1):38-43. PubMed ID: 17441316
[TBL] [Abstract][Full Text] [Related]
17. Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles.
Iwasaki I; Sugiyama H; Kanazawa S; Hemmi H
Cancer Chemother Pharmacol; 2002 Jun; 49(6):438-44. PubMed ID: 12107547
[TBL] [Abstract][Full Text] [Related]
18. Establishment of an in vitro model for cisplatin resistance in human neuroblastoma cell lines.
Ireland CM; Pittman SM; Jones SL; Harnett PR
Anticancer Res; 1994; 14(6B):2397-403. PubMed ID: 7872659
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo.
Johnsen JI; Lindskog M; Ponthan F; Pettersen I; Elfman L; Orrego A; Sveinbjörnsson B; Kogner P
Cancer Res; 2004 Oct; 64(20):7210-5. PubMed ID: 15492235
[TBL] [Abstract][Full Text] [Related]
20. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
